E-Mail
IMAGE: Novel cancer immunotherapy approach inverts a missing gene copy into an immune cell-activating signal. view more
Credit: Elizabeth Cook
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.
Genes have two alleles, or copies, with one copy inherited from each parent. Cancer-related genetic alterations commonly involve the loss of one of these gene copies.
Multisystem intervention could potentially prevent or reverse frailty, research shows
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Diagnosis of frailty is based on three or more of five key clinical signs and symptoms: weakness, slow walking speed, low level of physical activity, fatigue or exhaustion, and unintentional. view more
Credit: Jennifer Fairman
FOR IMMEDIATE RELEASE
Physicians understand frailty as a dysregulation among multiple systems in the body that make it less resilient and unable to recover completely when faced with a physical challenge such as injury or illness. Defining frailty on a scientific level, however, has been a challenging task, explains Ravi Varadhan, Ph.D., associate professor of oncology in the Division of Biostatistics and Bioinformatics at the Johns Hopkins Kimmel Cancer Center.
Genomic Test Helps Guide Precision Medicine to Estimate Risk of Prostate Cancer Metastasis, Death
February 11, 2021
San Francisco, CA (UroToday.com) A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.
Researchers studied prostate cancer samples from 352 participants in the NRG/RTOG 9601 clinical trial, which compared radiation therapy alone with radiation therapy combined with hormone therapy. The investigators found that the Decipher test, which measures the activity of 22 genes among seven known cancer pathways, independently estimated the participants’ risk of metastasis, death from prostate cancer, and overall survival. Researchers say it also guided treatment recommendations for recurrence of prostate cancer after surgery, helping identify patients most likely to bene
vimarsana © 2020. All Rights Reserved.